TITLE

Treatment of Gastric Ulcer

AUTHOR(S)
Juhl, Erik; Tygstrup, Niels; Christensen, Erik
PUB. DATE
March 1978
SOURCE
American Journal of Gastroenterology;Mar1978 Part 1, Vol. 69 Issue 3, p272
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Twenty-nine randomized clinical trials (RCTs) from the decade 1964-74 evaluating treatments of gastric ulcer have been analyzed. None of them fulfilled all criteria for an ideal RCT. The most frequent shortcomings were: short treatment or follow-up periods, incomplete description of the patients included, small patient samples, suboptimal experimental design, lack of double-blind testing, high number of drop-outs, less precise or less relevant types of evaluation of the treatment effect, uncontrolled ancillary treatment, or lack of statistical evaluation of the results. The most frequently tested drug was carbenoxolone, which has been shown to be clearly effective. Judged by the effect on the recommendations in standard medical textbooks the impact of the best RCTs have been small. This situation emphasizes the need for more well-planned and performed RCTs on treatments of gastric ulcer.
ACCESSION #
16209156

 

Related Articles

  • EULAR 2009.  // BioWorld Today;6/12/2009, Vol. 20 Issue 112, p7 

    The article reports on reports on the conclusion of Active Biotech's Phase Ib trial of the 57-57 SLE project. Lupus patients enrolled in the trial were treated for 12 weeks with the compound. The safety profile for the entire phase of the study was favorable. The compound is an oral...

  • Interim analysis supports Allos's Phase II lymphoma trial.  // PharmaWatch: Cancer;Feb2008, Vol. 7 Issue 2, p5 

    The article reports on the results of a clinical study evaluating Allos Therapeutics Inc.'s PDX drug in patients with relapsed or refractory peripheral T-cell lymphoma. In the 35 patients enrolled in the study, who completed at least one cycle of treatment with PDX, results of the interim...

  • Pain Therapeutics begins enrollment of patients for Oxytrex phase III trial.  // PharmaWatch: CNS;April 2004, Vol. 3 Issue 4, p13 

    Reports on the enrolment of patients for the clinical trial of the oral painkiller, Oxytrex, by Pain Therapeutics Inc. Use of the drug in treating patients who suffer from sever chronic pain; Detection of the ability of the painkiller to inhibit an excitatory effect of opioid receptors; Design...

  • ImmunoCellular Provides an Update on Enrollment for the Company's Phase II Clinical Trial.  // Biomedical Market Newsletter;5/12/2012, Vol. 21, p1 

    The article provides information on an update from ImmunoCellular Therapeutics Ltd. on the clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, a dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of...

  • Lymphoma Update.  // PharmaWatch: Cancer;Feb2007, Vol. 6 Issue 2, p4 

    The article reports developments related to the treatment of lymphoma. Allos Therapeutics Inc. reported that its trial for cancer drug PDX can go ahead after the Data Monitoring Committee conducted an interim analysis on its safety and made a recommendation to continue the study. Aeterna...

  • No correction, no retraction, no apology, no comment: paroxetine trial reanalysis raises questions about institutional responsibility. Doshi, Peter // BMJ: British Medical Journal;9/19/2015, Vol. 351 Issue 8025, ph4629 

    The article examines the resistance of the American Academy of Child and Adolescent Psychiatry (AACAP) to call for retraction of a paper written by psychiatrist Martin Keller on the Study 329 placebo-controlled, randomized controlled trial of paroxetine and imipramine for adolescents with...

  • ImmunoGen Inc Announces Positive Results in Trastuzumab Emtansine (T-DM1) EMILIA Phase III Trial.  // Biomedical Market Newsletter;4/1/2012, Vol. 21, p1 

    The article provides information on the announcement made by ImmunoGen Inc. regarding the positive topline results from its trastuzumab emtansine (T-DM1) EMILIA Phase III trial. Trastuzumab emtansine consists of a potent cancer-killing agent DM1 attached to the HER2-targeting antibody...

  • Antidepressants and adverse effects in young patients: uncovering the evidence. Herxheimer, Andrew; Mintzes, Barbara // CMAJ: Canadian Medical Association Journal;2/17/2004, Vol. 170 Issue 4, p487 

    Addresses the need for premarket clinical trials of antidepressants in order to determine their efficiency and the harmful effects they may have on young patients. Warning against the use of selective serotonin reuptake inhibitors; Duration of most randomized trials of antidepressants; Value of...

  • Phase II/III.  // Applied Clinical Trials;Jul2005, Vol. 14 Issue 7, p16 

    Provides information related to latest phase II/III clinical trials. Initiation of a trial for an inhalable form of treprostinil for pulmonary hypertension by Lung Rx; Efficacy of Fibrillex at improving symptoms of Amylois A Amyloidosis, based on Neurochem Inc.'s trial.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics